Research and Markets (http://www.researchandmarkets.com/research/bf1f27/bangladesh_pharmac) has announced the addition of the “Bangladesh Pharmaceuticals and Healthcare Report Q3 2008” report to their offering.
Bangladesh Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Bangladesh’s pharmaceuticals and healthcare industry.
The Bangladesh Pharmaceuticals & Healthcare Report Q308 is the most recent addition to BMI’s Industry Survey & Forecasts Series. It integrates data and narrative from market research firms, industry associations and company presentations to provide objective assessment of one of Asia Pacific’s most promising opportunities for drugmakers.
We calculate that the country’s pharmaceutical market had a valuation of US$700mn in 2007 and that a compound annual growth rate (CAGR) of 18.79% through to 2012 can be expected. This rapid market expansion is primarily due to greater uptake of medicine throughout this densely populated country, but also through appreciation of the data against the US dollar, population growth and increased government healthcare expenditure, among other factors.
2008 is proving a challenging year for drugmakers in Bangladesh. A round of price cuts is scheduled after a hiatus of two years. Sales forces of Bangladeshi drugmakers are growing exponentially, which results in significantly higher expenses. Meanwhile, the appreciation of both the Indian rupee and the Chinese yuan is boosting the cost of raw materials.
Eskayef was best performing company in Bangladesh during Q108, with sales up 21.12% on Q107, according to IMS Health. This compares favourably to the next fastest growing drugmakers: Renata (+16.19%), ACI (+16.17%) and Drug International (+13.79%), Incepta Pharma (+6.77%) and Square Pharma (+2.32%). Not all Bangladeshi pharmaceutical companies performed so well. Beximco Pharma witnessed a huge 42.04% drop in sales, while Acme recorded a 4.89% decrease.
The greatest challenge facing the industry is the end of the patent-free regime in 2016, when local pharmaceutical companies will have to cease the production, distribution and sale of medicine that have intellectual property protection elsewhere in the world. Forward thinking local drugmakers will have to adapt their product portfolio as necessary or suffer a steep drop-off in sales. However, the global ‘patent cliff’ in 2011 will mitigate this watershed.
Key Topics Covered:
Executive Summary
Bangladesh Pharmaceuticals And Healthcare Industry SW
Bangladesh Political SWOT
Bangladesh Economic SWOT
Bangladesh Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q308
Limits To Potential Returns
Risks To Realisation Of Returns
Market Summary
Regulatory Regime
Table: Steps Required To Establish Pharmaceutical Manufacturing Unit And Obtain A Drug Manufacturing Licence (DML)
Counterfeit Drugs
Intellectual Property
Pricing And Reimbursement Regime
Industry Trends And Developments
Epidemiology
Healthcare Sector
Recent Activities By Foreign Companies
Contract Manufacturing
Research And Development
Table: Suggestions Made By University Of Dhaka’s Faculty Of Pharmacy To Improve Pharmaceutical Research Standards
Industry Forecast Scenario
Overall Market Forecast
Table: Bangladeshi Drug Market Expenditure, 2003-2012
Key Growth Factors – Industry
Key Growth Factors – Macroeconomic
Table: Bangladesh – Economic Activity
Prescription Drug Market Forecast
Table: Bangladeshi Prescription Drug Market – Data And Forecasts (BDTmn, unless otherwise stated)
Patented Drug Market Forecast
Table: Bangladeshi Patented Drug Market – Data And Forecasts
Generics Market Forecast
Table: Bangladeshi Generics Market – Data And Forecasts
OTC Drug Market Forecast
Table: Bangladeshi OTC Drug Market – Data And Forecasts (BDTmn, unless otherwise stated)
Pharmaceutical Export/Import Forecast
Table: Bangladeshi Pharmaceutical Export/Import – Data And Forecast (US$mn)
Other Healthcare Data Forecasts
Table: Other Healthcare Data And Forecasts
Key Risks To BMI’s Forecasts
Competitive Landscape
Company Profiles
Eskayef Bangladesh
Square Pharmaceuticals
Renata
Beximco Pharmaceuticals
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodolo
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Companies Mentioned:
– Eskayef Bangladesh
– Square Pharmaceuticals
– Renata
– Beximco Pharmaceuticals
For more information visit http://www.researchandmarkets.com/research/bf1f27/bangladesh_pharmac
Comments